Answer
Selected formulations are licensed for chronic-phase Ph+ CML in children aged 6 years and older. Use is directed by a specialist paediatric haematology team.
Sources for this answer
- Bosulif 100 mg hard capsules — Current selected SmPCemc · Summary of Product Characteristics
- Bosulif 500mg Film Coated Tablets — Current selected SmPCemc · Summary of Product Characteristics
General medicine information. Follow the instructions for your own medicine and speak to a pharmacist or clinician about your individual circumstances.